Good news came from Fresenius Medical Care on Tuesday evening. The MDAX Group has ended its legal dispute with the US government and reached a settlement, which is why the forecast for the current year is being raised. The stock reacted to the rally with a slight rise in late trade.
Related lawsuits have already been filed in the US in 2019. As a result of the legally binding settlement, there is now a positive impact on the operating result of around 175 million euros. Fresenius Medical Care has now revised its forecast accordingly.
The group had previously expected operating profit to increase in the low single-digit percentage range compared to the 1.54 billion euros at the end of the previous year. At present, the target has been fixed at 12 to 14 percent. All other elements of the perspective remain unchanged.
Fresenius Medical Care
(WKN: 578580)
Charge must be evaluated positively. However, the special effect of comparison is unlikely to raise prices in the long run. This is also shown by the stock’s only small reaction to increased forecasting. FMC is shareholder cautious. Mother Fresenius is very attractive right now.
“Amateur coffee fan. Travel guru. Subtly charming zombie maven. Incurable reader. Web fanatic.”
More Stories
Martin Schulz: “I want more courage for the United States of Europe”
US reports first case of H5N1 bird flu virus in pigs
Polestar fears US sales ban